We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Device Products » Advertising & Promotion - Webinar Recording/Transcript

Other Options

Audio Recording/Transcript - April 26, 2018

$287.00

Audio Recording/Transcript - April 26, 2018

$258.00

Audio Recording/Transcript - April 26, 2018

$244.00

Audio Recording/Transcript - April 26, 2018

$230.00

Audio Recording/Transcript - April 26, 2018

$215.00

Advertising & Promotion - Webinar Recording/Transcript

$287.00
Device Products

Product Details

Advertising & Promotion: Compliance Tips from Recent Warning and Untitled Letters

Drug and device makers must advertise to survive, but the legal issues surrounding advertising and promotion are far from settled. FDA enforcement actions don’t seem to show a consistent pattern, leaving you to guess whether a warning letter lurks ahead and how to avoid it.

But the FDA has left a paper trail in recently issued untitled and warning letters. Now, two of Washington’s top FDA lawyers have analyzed those documents and teased out patterns to help you stay in the clear.

In a fast-paced hour and half heavy on case studies and analysis, Kellie Combs Esq. and Josh Oyster Esq. of Ropes & Gray LLP disclose: 

  • FDA enforcement priorities: What on-the-record actions tell you about how the agency actually views presentation of false or misleading risk information and other hot-button issues
  • Specifically: Safety and risk information; Communicating pre-approval; describing FDA-approved or -cleared uses; disclaimers and contextualizing information
  • Case studies: How historical enforcement may interplay with recent draft guidance on manufacturer communications, including use of subgroup analyses and patient-reported outcomes
  • Tips for responding to warning and untitled letters and implementing corrective action plans
  • Best practices for promotional review committees, including committee composition, scope of covered materials and review guidelines
  • And much more!
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing